• Home
  • »
  • Biotechnology
  • »
  • Viral Vector And Plasmid DNA Manufacturing Market Report, 2030
GVR Report cover Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Report

Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-695-0
  • Number of Report Pages: 120
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2022
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Market Size & Trends

The global viral vector and plasmid DNA manufacturing market size was estimated at USD 5.33 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2030. One of the primary factors driving the market is the advancement in gene therapy, as the development of new gene therapies is heavily reliant on high-quality viral vectors and plasmid DNA. Furthermore, improvements in manufacturing processes have made it possible to produce viral vectors and plasmid DNA more efficiently at larger scales, while also reducing costs and improving overall quality.

U.S. Viral Vector And Plasmid DNA Manufacturing Market size and growth rate, 2024 - 2030

Increase in investments in cell and gene therapy research space, there is exceptional demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Furthermore, an increase in the adoption of single-use equipment coupled with the use of suspension-based cell culture is the current industry trend. Utilizing disposable equipment improves productivity and flexibility, resulting in high final product yields. Thus, advancements in single-use technology directly impact the vector production market. Pall Corporation—one of the key companies—offers single-use equipment suitable for viral vector manufacturing. The PALL iCELLis is a single-use fixed-bed bioreactor that offers large-scale manufacturing of viral vectors in an adherent environment. Thus, an increase in the implementation of single-use technology in vector production facilities is expected to impact market growth in the coming years significantly.

The COVID-19 pandemic has created lucrative opportunities for market players by allowing them to shift their business focus toward the development of viral vectors for the SARS-CoV-2 vaccine. Viral vectors are commonly employed tools used in the discovery and development of vaccines against SARS-CoV-2. The ongoing COVID-19 pandemic has encouraged investment in this space in search of a vaccine as viral vector-based vaccines can be manufactured and designed relatively quickly with the use of same building blocks. However, viral vectors were being studied extensively by research communities well before the COVID-19 pandemic. This is because of their proven efficiency and successful application in gene and cell therapies. With the COVID-19 outbreak, applications of viral vectors were repurposed to manufacture vaccines. Although successful, viral vector manufacturing workflows face considerable challenges concerning process and scale. Thus, technology and platform developers are making significant attempts to simplify the viral vector production process.

Market Concentration & Characteristics

The viral vectors and plasmid DNA manufacturing market has witnessed a significant degree of innovation in recent years. With the increasing demand for advanced gene therapy and vaccine development, manufacturers are constantly exploring new and efficient ways to produce viral vectors and plasmid DNA. One of the key innovations in this market is the use of transient transfection technology for the large-scale production of viral vectors. Another area of innovation is the use of suspension cell culture systems for viral vector production.

Viral Vector And Plasmid DNA Manufacturing Market Concentration & Characteristics

Large pharmaceutical and biotechnology companies are increasingly acquiring smaller vector and plasmid DNA manufacturers to access their proprietary technologies, expertise, and production capacity. This leads to consolidation within the market, giving established players greater control over pricing and market share. Smaller companies benefit from the resources and infrastructure of larger acquirers, enabling them to scale up their operations and reach a wider audience. For instance, in February 2022, Merck KGaA acquired Exelead for about USD 780 million. This would further enhance Merck’s Life Science portfolio to offer end users complete end-to-end CDMO services across the mRNA value chain.

The impact of regulations on the viral vectors and plasmid DNA manufacturing market is significant, influencing product development, manufacturing processes, and market dynamics. Compliance with regulatory standards is essential for ensuring patient safety, maintaining product quality, and gaining market access. Manufacturers need to navigate these regulatory landscapes effectively to bring innovative gene therapies to patients while meeting the stringent requirements set by regulatory agencies.

As of now, viral vectors and plasmid DNA remain a crucial component of many gene therapy treatments and there is no direct substitute available in the market that can match their effectiveness.

The end user concentration in the viral vectors and plasmid DNA manufacturing market varies depending on the specific application. In some cases, academic and research institutions are the primary end users, while in others, biopharmaceutical companies and contract manufacturing organizations (CMOs) may dominate. However, with the increasing focus on gene therapy and the growing demand for viral vectors and plasmid DNA, it is expected that biopharmaceutical companies will become the major end users shortly.

Vector Type Insights

Based on the vector type, the adeno-associated virus (AAV) segment led the market with a largest revenue share of 20% in 2023. AAVs are in huge demand and their utilization in clinical trials is increasing rapidly as these viruses offer maximum precision in delivering the gene to the region of interest. The increasing adoption is due to clinical trials relating to the development of orthopedic and ocular gene therapy therapies exhibiting increased efficiency and efficacy. In August 2022, an article published in Springer stated that AAV-mediated gene therapy could prevent acquired hearing loss. Application of AAV is rising significantly across various therapeutic areas, thereby witnessing a boost in its adoption rate.

The lentivirus segment is expected to grow at a significant CAGR over the forecast period. Increasing use of lentiviral vectors in ongoing research areas, the research industry is focusing on advancements in these vectors. For instance, scientists are studying the potential of non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis. NILVs can transduce both non-dividing and dividing cells. These vectors have potential applications in CAR-T cell therapy research. Furthermore, a recent study published in June 2022 stated that lentiviral vectors are being used to develop vaccines that specifically target dendritic cells and stimulate a powerful T-cell immune response. These factors are expected to support market growth in the forecast years.

Workflow Insights

Based on the workflow, the downstream processing segment dominated the market in 2023 with a largest revenue share of 53.3%, owing to highly complex procedures carried out for polishing and purification of clinical grade final products. Increase in demand for clinical grade viral vectors, manufacturers are involved in development of novel economic downstream processes to address the challenges associated with conventional lab-scale manufacturing of vectors and is expected to support market growth. For example, combining a fed-batch fermentation technique and genetically optimized cell systems with conventional and novel technologies for the purification of vectors.

The upstream processing segment is expected to grow at significant CAGR over the forecast period. Upstream processing involves infecting cells with virus, cultivating of cells, and harvesting the virus from cells. Advanced product development, such as ambr 15 microbioreactor system for high-throughput upstream process development, is expected to drive the segment. ambr 15 microbioreactor system allows efficient cell culture processing with automated experimental set up and sampling, which requires less labor and laboratory space and time taken for cleaning and sterilization is also very less.

Application Insights

Based on the application, the vaccinology segment dominated the market in 2023 with a largest revenue share of 22.0%. The increasing demand for vaccines for various diseases, such as cancer and infectious diseases like COVID-19, primarily drives this growth. Viral vectors and plasmid DNA are widely used in the development of vaccines, and the increasing emphasis on research and development of new vaccines is expected to drive the growth of this market segment. In addition, the availability of government funding for vaccine development programs is also contributing to the growth of the vaccinology application in the viral vectors and plasmid DNA manufacturing market.

The cell therapy segment is expected to grow at the fastest CAGR over the forecast period owing to increase in personalized cancer treatments. Moreover, the success of Chimeric Antigen Receptor (CAR)-based cell therapies for cancer treatment is expected to further fuel the market growth.

End-use Insights

Based on the end use, the research institutes segment dominated the market with the largest revenue share of 58.0% in 2023. Research activities carried out pertaining to improvement in vector production by research entities is driving the segment. For instance, in July 2021, Bluebird Bio and the Institute for NanoBiotechnology entered a research collaboration to develop novel technologies that boost the production of viral vectors for development of novel gene therapies. The researchers at Institute of NanoBiotechnology developed a highly effective and shelf-stable formulation of ready-to-dose form of DNA particles for producing viral vectors. Increasing number of such research collaborations are expected to fuel market growth.

The pharmaceutical and biotechnology companies segment is expected to grow significant CAGR over the forecast period. This can be attributed to continuous introduction of advanced therapies coupled with subsequent increase in the number of gene therapy-based research programs by pharmaceutical firms. The number of biotech companies that are employing vectors for therapeutics production continues to increase over time.

Disease Insights

Based on the disease, the cancer segment dominated the market in 2023 with a largest revenue share of 37.9%. According to Globocan, the number of new cancer cases is anticipated to reach 28.4 million within the next two decades, with a rise of 47% from 2020, owing to adoption of western lifestyle, high consumption of alcohol, smoking, poor diet choices, and physical inactivity. Growing number of cancer cases is projected to propel the demand for gene therapies to treat cancer patients, consequently, increasing demand for viral vectors and plasmid DNA for the development of these gene therapies.

Global Viral Vector And Plasmid DNA Manufacturing Market share and size, 2023

The genetic disorders are expected to register the significant CAGR during the forecast period. Genetic disorders are the most focused area of application for gene therapy, with more than 10% of ongoing clinical trials directed toward the same. This makes gene therapy for genetic disorders one of the most crucial markets in the forecast years and it expected to support growth of viral vectors and plasmid DNA manufacturing market.

Regional Insights

North America dominated the market and accounted for 48.96% share in 2023. This can be attributed to the growing engagement of companies in research and product development in gene & cell therapy coupled with a substantial number of contract development organizations in the region. In addition, homegrown companies are expanding their manufacturing facilities in the region.The U.S. held the highest revenue share in North America viral vectors and plasmid DNA manufacturing market owing to the presence of key market players, including CDMOs offering GMP manufacturing services, and the adoption of highly innovative manufacturing technologies for production.

Viral Vector And Plasmid DNA Manufacturing Market Trends, by Region, 2024 - 2030

Asia Pacific is expected to be the fastest-growing region with a CAGR during the forecast period. China is one of the leading countries due to advancements in the regulatory framework for cell-based research activities in the country contributing to the Asia Pacific market growth. Increasing development and commercialization of novel vaccines in the China is also expected to contribute to market growth. For instance, in January 2021, Advaccine Biopharmaceuticals Suzhou Co., Ltd and INOVIO signed licensing agreement to commercialize INO-800—a COVID-19 DNA vaccine—in greater China area, including Taiwan, Hong Kong, Macao, and Mainland China.

The viral vectors and plasmid DNA manufacturing market in China is experiencing significant growth due to increased demand for gene therapies, advancements in biotechnology, and supportive government initiatives. The country's expanding biopharmaceutical sector, coupled with a large patient population, creates a robust market for the manufacturing of viral vectors and plasmid DNA, driving industry growth.

Key Viral Vector And Plasmid DNA Manufacturing Company Insights

Some of the key players operating in the market include Charles River Laboratories, Waisman Biomanufacturing, Genezen laboratories, Batavia Biosciences, Miltenyi Biotec GmbH, Wuxi Biologics, RegenxBio, Inc., Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Inc. Major companies are focusing on collaborations, partnerships, and expansions to compete in the global market.

Key Viral Vector And Plasmid DNA Manufacturing Companies:

The following are the leading companies in the viral vector and plasmid DNA manufacturing market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these viral vector and plasmid DNA manufacturing companies are analyzed to map the supply network. 

  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • Wuxi Biologics
  • Takara Bio Inc.
  • Waisman Biomanufacturing
  • Genezen laboratories
  • Batavia Biosciences
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • Audentes Therapeutics
  • BioMarin Pharmaceutical
  • RegenxBio, Inc.

Recent Developments

  • In October 2023, AGC Biologics announced that they will be expanding their pDNA manufacturing facility in Germany. This is expected to help the company to reduce the time required for manufacturing

  • In February 2023, BioNTech SE announced that they have completed the setup of first plasmid DNA manufacturing plant of theirs in Germany. This has enabled the company to manufacture pDNA independently for clinical and commercial applications

  • In April 2022, FUJIFILM Holdings Corporation acquired a cell therapy manufacturing unit from Atara Biotherapeutics, Inc. The company will help the manufacturing of Atara's commercial-and clinical stage allogeneic cell therapies at the unit as part of the manufacturing and services agreement

  • In July 2022, Charles River Laboratories announced the launch of the Plasmid DNA Centre of Excellence in the UK. The expansion comes after Charles River acquired Cognate BioServices and Cobra Biologics, two innovative contract development and production companies for plasmid DNA, viral vectors, and cell therapy (CDMOs)

  • In January 2022, WuXi Biologics entered a long-term collaboration with Shanghai BravoBio Co., Ltd to accelerate the development of innovative vaccines, to address the growing challenge of infectious diseases

Viral Vector And Plasmid DNA Manufacturing Market Report Scope 

Report Attribute

Details

Market size value in 2024

USD 6.47 billion

Revenue forecast in 2030

USD 19.5 billion

Growth rate

CAGR of 20.2% from 2024 to 2030

Base year for estimation

2023

Historical data

2018 – 2022

Forecast period

2024 – 2030

Report updated

January, 2024

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Vector type, workflow, application, end-use, disease, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait

Key companies profiled

Merck KGaA, Lonza; FUJIFILM Diosynth Biotechnologies; Thermo Fisher Scientific; Cobra Biologics; Catalent Inc.; Wuxi Biologics; TakarBio Inc.; Waisman Biomanufacturing; Genezen laboratories; Batavia Biosciences; Miltenyi Biotec GmbH; SIRION Biotech GmbH; Virovek Incorporation; BioNTech IMFS GmbH; Audentes Therapeutics; BioMarin Pharmaceutical; RegenxBio, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Viral Vector And Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the viral vector and plasmid DNA manufacturing market report based on vector type, workflow, application, end use, disease, and region:

  • Vector Type Outlook (Revenue, USD Billion, 2018 - 2030)

    • Adenovirus

    • Retrovirus

    • Adeno-Associated Virus (AAV)

    • Lentivirus

    • Plasmids

    • Others

  • Workflow Outlook (Revenue, USD Billion, 2018 - 2030)

    • Upstream Manufacturing

      • Vector Amplification & Expansion

      • Vector Recovery/Harvesting

    • Downstream Manufacturing

      • Purification

      • Fill Finish

  • Application Outlook (Revenue, USD Billion, 2018 - 2030)

    • Antisense & RNAi Therapy

    • Gene Therapy

    • Cell Therapy

    • Vaccinology

    • Research Applications

  • End-use Outlook (Revenue, USD Billion, 2018 - 2030)

    • Pharmaceutical and Biopharmaceutical Companies

    • Research Institutes

  • Disease Outlook (Revenue, USD Billion, 2018 - 2030)

    • Cancer

    • Genetic Disorders

    • Infectious Diseases

    • Others

  • Regional Outlook (Revenue, USD Billion, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

      • France

      • Spain

      • Italy

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Vector type
                        1.2.2. Workflow
                        1.2.3. Application
                        1.2.4. End-use
                        1.2.5. Disease
                        1.2.6. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
                            3.2.1.2. Technological Advancements in Manufacturing Vectors
                            3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
                        3.2.2. Market restraint analysis
                            3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
                    3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
                        3.3.1. Industry Analysis – Porter’s
                        3.3.2. PESTEL Analysis
                        3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
                    4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
                    4.2. Adeno-associated virus (AAV)
                        4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    4.3. Lentivirus
                        4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    4.4. Adenovirus
                        4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    4.5. Retrovirus
                        4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    4.6. Plasmids
                        4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    4.7. Others
                        4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
                    5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
                    5.2. Upstream Manufacturing
                        5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                        5.2.2. Vector Amplification & Expansion
                            5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                        5.2.3. Vector Recovery/Harvesting
                            5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    5.3. Downstream Manufacturing
                        5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                        5.3.2. Purification
                            5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                        5.3.3. Fill Finish diagnostic instruments
                            5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
                    6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
                    6.2. Gene Therapy
                        6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    6.3. Cell Therapy
                        6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    6.4. Vaccinology
                        6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    6.5. Research Applications
                        6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
                    7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
                    7.2. Pharmaceutical and Biopharmaceutical Companies
                        7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    7.3. Research Institutes
                        7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
                    8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
                    8.2. Cancer
                        8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    8.3. Genetic Disorders
                        8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    8.4. Infectious Diseases
                        8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
                    8.5. Other
                        8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
                    9.1. Regional Market Share Analysis, 2023 & 2030
                    9.2. North America
                        9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
                        9.2.2. U.S.
                            9.2.2.1. Key country dynamics
                            9.2.2.2. Regulatory framework
                            9.2.2.3. Competitive scenario
                            9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
                            9.2.2.5. Target disease prevalence
                        9.2.3. Canada
                            9.2.3.1. Key country dynamics
                            9.2.3.2. Regulatory framework
                            9.2.3.3. Competitive scenario
                            9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
                            9.2.3.5. Target disease prevalence
                    9.3. Europe
                        9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
                        9.3.2. UK
                            9.3.2.1. Key country dynamics
                            9.3.2.2. Regulatory framework
                            9.3.2.3. Competitive scenario
                            9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.2.5. Target disease prevalence
                        9.3.3. Germany
                            9.3.3.1. Key country dynamics
                            9.3.3.2. Regulatory framework
                            9.3.3.3. Competitive scenario
                            9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.3.5. Target disease prevalence
                        9.3.4. France
                            9.3.4.1. Key country dynamics
                            9.3.4.2. Regulatory framework
                            9.3.4.3. Competitive scenario
                            9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.4.5. Target disease prevalence
                        9.3.5. Italy
                            9.3.5.1. Key country dynamics
                            9.3.5.2. Regulatory framework
                            9.3.5.3. Competitive scenario
                            9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.5.5. Target disease prevalence
                        9.3.6. Spain
                            9.3.6.1. Key country dynamics
                            9.3.6.2. Regulatory framework
                            9.3.6.3. Competitive scenario
                            9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.6.5. Target disease prevalence
                        9.3.7. Norway
                            9.3.7.1. Key country dynamics
                            9.3.7.2. Regulatory framework
                            9.3.7.3. Competitive scenario
                            9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.7.5. Target disease prevalence
                        9.3.8. Sweden
                            9.3.8.1. Key country dynamics
                            9.3.8.2. Regulatory framework
                            9.3.8.3. Competitive scenario
                            9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.8.5. Target disease prevalence
                        9.3.9. Denmark
                            9.3.9.1. Key country dynamics
                            9.3.9.2. Regulatory framework
                            9.3.9.3. Competitive scenario
                            9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
                            9.3.9.5. Target disease prevalence
                    9.4. Asia Pacific
                        9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
                        9.4.2. Japan
                            9.4.2.1. Key country dynamics
                            9.4.2.2. Regulatory framework
                            9.4.2.3. Competitive scenario
                            9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.2.5. Target disease prevalence
                        9.4.3. China
                            9.4.3.1. Key country dynamics
                            9.4.3.2. Regulatory framework
                            9.4.3.3. Competitive scenario
                            9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.3.5. Target disease prevalence
                        9.4.4. India
                            9.4.4.1. Key country dynamics
                            9.4.4.2. Regulatory framework
                            9.4.4.3. Competitive scenario
                            9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.4.5. Target disease prevalence
                        9.4.5. Australia
                            9.4.5.1. Key country dynamics
                            9.4.5.2. Regulatory framework
                            9.4.5.3. Competitive scenario
                            9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.5.5. Target disease prevalence
                        9.4.6. South Korea
                            9.4.6.1. Key country dynamics
                            9.4.6.2. Regulatory framework
                            9.4.6.3. Competitive scenario
                            9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.6.5. Target disease prevalence
                        9.4.7. Thailand
                            9.4.7.1. Key country dynamics
                            9.4.7.2. Regulatory framework
                            9.4.7.3. Competitive scenario
                            9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
                            9.4.7.5. Target disease prevalence
                    9.5. Latin America
                        9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
                        9.5.2. Brazil
                            9.5.2.1. Key country dynamics
                            9.5.2.2. Regulatory framework
                            9.5.2.3. Competitive scenario
                            9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
                            9.5.2.5. Target disease prevalence
                        9.5.3. Mexico
                            9.5.3.1. Key country dynamics
                            9.5.3.2. Regulatory framework
                            9.5.3.3. Competitive scenario
                            9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
                            9.5.3.5. Target disease prevalence
                        9.5.4. Argentina
                            9.5.4.1. Key country dynamics
                            9.5.4.2. Regulatory framework
                            9.5.4.3. Competitive scenario
                            9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
                            9.5.4.5. Target disease prevalence
                    9.6. MEA
                        9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
                        9.6.2. South Africa
                            9.6.2.1. Key country dynamics
                            9.6.2.2. Regulatory framework
                            9.6.2.3. Competitive scenario
                            9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
                            9.6.2.5. Target disease prevalence
                        9.6.3. Saudi Arabia
                            9.6.3.1. Key country dynamics
                            9.6.3.2. Regulatory framework
                            9.6.3.3. Competitive scenario
                            9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
                            9.6.3.5. Target disease prevalence
                        9.6.4. UAE
                            9.6.4.1. Key country dynamics
                            9.6.4.2. Regulatory framework
                            9.6.4.3. Competitive scenario
                            9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
                            9.6.4.5. Target disease prevalence
                        9.6.5. Kuwait
                            9.6.5.1. Key country dynamics
                            9.6.5.2. Regulatory framework
                            9.6.5.3. Competitive scenario
                            9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
                            9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
                    10.1. Company Categorization
                    10.2. Strategy Mapping
                    10.3. Company Market Position Analysis, 2023
                    10.4. Company Profiles/Listing
                        10.4.1. Merck KGaA
                            10.4.1.1. Company overview
                            10.4.1.2. Financial performance
                            10.4.1.3. Product benchmarking
                            10.4.1.4. Strategic initiatives
                        10.4.2. Lonza
                            10.4.2.1. Company overview
                            10.4.2.2. Financial performance
                            10.4.2.3. Product benchmarking
                            10.4.2.4. Strategic initiatives
                        10.4.3. FUJIFILM Diosynth Biotechnologies
                            10.4.3.1. Company overview
                            10.4.3.2. Financial performance
                            10.4.3.3. Product benchmarking
                            10.4.3.4. Strategic initiatives
                        10.4.4. Thermo Fisher Scientific
                            10.4.4.1. Company overview
                            10.4.4.2. Financial performance
                            10.4.4.3. Product benchmarking
                            10.4.4.4. Strategic initiatives
                        10.4.5. Cobra Biologics
                            10.4.5.1. Company overview
                            10.4.5.2. Financial performance
                            10.4.5.3. Product benchmarking
                            10.4.5.4. Strategic initiatives
                        10.4.6. Catalent Inc.
                            10.4.6.1. Company overview
                            10.4.6.2. Financial performance
                            10.4.6.3. Product benchmarking
                            10.4.6.4. Strategic initiatives
                        10.4.7. Wuxi Biologics
                            10.4.7.1. Company overview
                            10.4.7.2. Financial performance
                            10.4.7.3. Product benchmarking
                            10.4.7.4. Strategic initiatives
                        10.4.8. Takara Bio Inc.
                            10.4.8.1. Company overview
                            10.4.8.2. Financial performance
                            10.4.8.3. Product benchmarking
                            10.4.8.4. Strategic initiatives
                        10.4.9. Waisman Biomanufacturing
                            10.4.9.1. Company overview
                            10.4.9.2. Financial performance
                            10.4.9.3. Product benchmarking
                            10.4.9.4. Strategic initiatives
                        10.4.10. Genezen laboratories
                            10.4.10.1. Company overview
                            10.4.10.2. Financial performance
                            10.4.10.3. Product benchmarking
                            10.4.10.4. Strategic initiatives
                        10.4.11. Batavia Biosciences
                            10.4.11.1. Company overview
                            10.4.11.2. Financial performance
                            10.4.11.3. Product benchmarking
                            10.4.11.4. Strategic initiatives
                        10.4.12. Miltenyi Biotec GmbH
                            10.4.12.1. Company overview
                            10.4.12.2. Financial performance
                            10.4.12.3. Product benchmarking
                            10.4.12.4. Strategic initiatives
                        10.4.13. SIRION Biotech GmbH
                            10.4.13.1. Company overview
                            10.4.13.2. Financial performance
                            10.4.13.3. Product benchmarking
                            10.4.13.4. Strategic initiatives
                        10.4.14. Virovek Incorporation
                            10.4.14.1. Company overview
                            10.4.14.2. Financial performance
                            10.4.14.3. Product benchmarking
                            10.4.14.4. Strategic initiatives
                        10.4.15. BioNTech IMFS GmbH
                            10.4.15.1. Company overview
                            10.4.15.2. Financial performance
                            10.4.15.3. Product benchmarking
                            10.4.15.4. Strategic initiatives
                        10.4.16. Audentes Therapeutics
                            10.4.16.1. Company overview
                            10.4.16.2. Financial performance
                            10.4.16.3. Product benchmarking
                            10.4.16.4. Strategic initiatives
                        10.4.17. BioMarin Pharmaceutical
                            10.4.17.1. Company overview
                            10.4.17.2. Financial performance
                            10.4.17.3. Product benchmarking
                            10.4.17.4. Strategic initiatives
                        10.4.18. RegenxBio, Inc.
                            10.4.18.1. Company overview
                            10.4.18.2. Financial performance
                            10.4.18.3. Product benchmarking
                            10.4.18.4. Strategic initiatives


List of Tables

Table 1 List of abbreviation
Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 64 Asia Pacific viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
Table 65 Asia Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 66 Asia Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 67 Asia Pacific viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 68 Asia Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 69 Asia Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018 - 2030 (USD Million)
Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)
Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018 - 2030 (USD Million)
Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018 - 2030 (USD Million)
Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018 - 2030 (USD Million)
Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018 - 2030 (USD Million)
Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
Fig. 19 Adenovirus market estimates and forecast, 2018 - 2030
Fig. 20 Retrovirus market estimates and forecast, 2018 - 2030
Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018 - 2030
Fig. 22 Lentivirus market estimates and forecast, 2018 - 2030
Fig. 23 Plasmids market estimates and forecast, 2018 - 2030
Fig. 24 Others market estimates and forecast, 2018 - 2030
Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
Fig. 27 Upstream manufacturing market estimates and forecasts, 2018 - 2030
Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018 - 2030
Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018 - 2030
Fig. 30 Downstream manufacturing market estimates and forecasts, 2018 - 2030
Fig. 31 Purification market estimates and forecasts, 2018 - 2030
Fig. 32 Fill finish market estimates and forecasts, 2018 - 2030
Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018 - 2030
Fig. 36 Gene Therapy market estimates and forecasts, 2018 - 2030
Fig. 37 Cell Therapy market estimates and forecasts, 2018 - 2030
Fig. 38 Vaccinology market estimates and forecasts, 2018 - 2030
Fig. 39 Research Applications market estimates and forecasts, 2018 - 2030
Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018 - 2030
Fig. 43 Research institutes market estimates and forecasts, 2018 - 2030
Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 46 Cancer market estimates and forecasts, 2018 - 2030
Fig. 47 Genetic disorders market estimates and forecasts, 2018 - 2030
Fig. 48 Infectious Diseases market estimates and forecasts, 2018 - 2030
Fig. 49 Others market estimates and forecasts, 2018 - 2030
Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
Fig. 53 North America, by country
Fig. 54 North America
Fig. 55 North America market estimates and forecasts, 2018 - 2030
Fig. 56 U.S.
Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
Fig. 58 Canada
Fig. 59 Canada market estimates and forecasts, 2018 - 2030
Fig. 60 Europe
Fig. 61 Europe market estimates and forecasts, 2018 - 2030
Fig. 62 UK
Fig. 63 UK market estimates and forecasts, 2018 - 2030
Fig. 64 Germany
Fig. 65 Germany market estimates and forecasts, 2018 - 2030
Fig. 66 France
Fig. 67 France market estimates and forecasts, 2018 - 2030
Fig. 68 Italy
Fig. 69 Italy market estimates and forecasts, 2018 - 2030
Fig. 70 Spain
Fig. 71 Spain market estimates and forecasts, 2018 - 2030
Fig. 72 Denmark
Fig. 73 Denmark market estimates and forecasts, 2018 - 2030
Fig. 74 Sweden
Fig. 75 Sweden market estimates and forecasts, 2018 - 2030
Fig. 76 Norway
Fig. 77 Norway market estimates and forecasts, 2018 - 2030
Fig. 78 Asia Pacific
Fig. 79 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 80 China
Fig. 81 China market estimates and forecasts, 2018 - 2030
Fig. 82 Japan
Fig. 83 Japan market estimates and forecasts, 2018 - 2030
Fig. 84 India
Fig. 85 India market estimates and forecasts, 2018 - 2030
Fig. 86 Thailand
Fig. 87 Thailand market estimates and forecasts, 2018 - 2030
Fig. 88 South Korea
Fig. 89 South Korea market estimates and forecasts, 2018 - 2030
Fig. 90 Australia
Fig. 91 Australia market estimates and forecasts, 2018 - 2030
Fig. 92 Latin America
Fig. 93 Latin America market estimates and forecasts, 2018 - 2030
Fig. 94 Brazil
Fig. 95 Brazil market estimates and forecasts, 2018 - 2030
Fig. 96 Mexico
Fig. 97 Mexico market estimates and forecasts, 2018 - 2030
Fig. 98 Argentina
Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
Fig. 100 Middle East and Africa
Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 102 South Africa
Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
Fig. 104 Saudi Arabia
Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 106 UAE
Fig. 107 UAE market estimates and forecasts, 2018 - 2030
Fig. 108 Kuwait
Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Market Segmentation 

  • Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Adenovirus
    • Retrovirus
    • Adeno-Associated Virus (AAV)
    • Lentivirus
    • Plasmids
    • Others
  • Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
    • Upstream Manufacturing
      • Vector Amplification & Expansion
      • Vector Recovery/Harvesting
    • Downstream Manufacturing
      • Purification
      • Fill Finish
  • Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
    • Antisense & RNAi Therapy
    • Gene Therapy
    • Cell Therapy
    • Vaccinology
    • Research Applications
  • Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
    • Pharmaceutical and Biopharmaceutical Companies
    • Research Institutes
  • Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
    • Cancer
    • Genetic Disorders
    • Infectious Diseases
    • Others
  • Viral Vectors And Plasmid DNA Manufacturing Regional Outlook (Revenue, USD 2018 - 2030)
    • North America
      • North America Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Adenovirus
        • Retrovirus
        • Adeno-Associated Virus (AAV)
        • Lentivirus
        • Plasmids
        • Others
      • North America Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
        • Upstream Manufacturing
          • Vector Amplification & Expansion
          • Vector Recovery/Harvesting
        • Downstream Manufacturing
          • Purification
          • Fill Finish
      • North America Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Antisense & RNAi Therapy
        • Gene Therapy
        • Cell Therapy
        • Vaccinology
        • Research Applications
      • North America Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
        • Pharmaceutical and Biopharmaceutical Companies
        • Research Institutes
      • North America Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
        • Cancer
        • Genetic Disorders
        • Infectious Diseases
        • Others
      • U.S.
        • U.S. Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • U.S. Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • U.S. Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • U.S. Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • U.S. Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Canada
        • Canada Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Canada Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Canada Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Canada Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Canada Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
    • Europe
      • Europe Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Adenovirus
        • Retrovirus
        • Adeno-Associated Virus (AAV)
        • Lentivirus
        • Plasmids
        • Others
      • Europe Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
        • Upstream Manufacturing
          • Vector Amplification & Expansion
          • Vector Recovery/Harvesting
        • Downstream Manufacturing
          • Purification
          • Fill Finish
      • Europe Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Antisense & RNAi Therapy
        • Gene Therapy
        • Cell Therapy
        • Vaccinology
        • Research Applications
      • Europe Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
        • Pharmaceutical and Biopharmaceutical Companies
        • Research Institutes
      • Europe Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
        • Cancer
        • Genetic Disorders
        • Infectious Diseases
        • Others
      • Germany
        • Germany Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Germany Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Germany Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Germany Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Germany Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • U.K.
        • U.K. Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • U.K. Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • U.K. Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • U.K. Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • U.K. Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • France
        • France Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • France Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • France Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • France Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • France Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Spain
        • Spain Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Spain Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Spain Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Spain Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Spain Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Italy
        • Italy Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Italy Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Italy Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Italy Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Italy Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Denmark
        • Denmark Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Denmark Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Denmark Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Denmark Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Denmark Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Sweden
        • Sweden Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Sweden Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Sweden Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Sweden Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Sweden Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Norway
        • Norway Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Norway Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Norway Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Norway Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Norway Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
    • Asia Pacific
      • Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Adenovirus
        • Retrovirus
        • Adeno-Associated Virus (AAV)
        • Lentivirus
        • Plasmids
        • Others
      • Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
        • Upstream Manufacturing
          • Vector Amplification & Expansion
          • Vector Recovery/Harvesting
        • Downstream Manufacturing
          • Purification
          • Fill Finish
      • Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Antisense & RNAi Therapy
        • Gene Therapy
        • Cell Therapy
        • Vaccinology
        • Research Applications
      • Asia Pacific Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
        • Pharmaceutical and Biopharmaceutical Companies
        • Research Institutes
      • Asia Pacific Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
        • Cancer
        • Genetic Disorders
        • Infectious Diseases
        • Others
      • Japan
        • Japan Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Japan Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Japan Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Japan Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Japan Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • China
        • China Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • China Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • China Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • China Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • China Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • India
        • India Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • India Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • India Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • India Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Indiaa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Thailand
        • Thailand Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Thailand Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Thailand Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Thailand Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Thailand Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • South Korea
        • South Korea Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • South Korea Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • South Korea Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • South Korea Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • South Korea Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Australia
        • Australia Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Australia Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Australia Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Australia Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Australia Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
    • Latin America
      • Latin America Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Adenovirus
        • Retrovirus
        • Adeno-Associated Virus (AAV)
        • Lentivirus
        • Plasmids
        • Others
      • Latin America Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
        • Upstream Manufacturing
          • Vector Amplification & Expansion
          • Vector Recovery/Harvesting
        • Downstream Manufacturing
          • Purification
          • Fill Finish
      • Latin America Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Antisense & RNAi Therapy
        • Gene Therapy
        • Cell Therapy
        • Vaccinology
        • Research Applications
      • Latin America Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
        • Pharmaceutical and Biopharmaceutical Companies
        • Research Institutes
      • Latin America Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
        • Cancer
        • Genetic Disorders
        • Infectious Diseases
        • Others
      • Brazil
        • Brazil Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Brazil Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Brazil Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Brazil Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Brazil Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Mexico
        • Mexico Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Mexico Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Mexico Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Mexico Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Mexico Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Argentina
        • Argentina Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Argentina Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Argentina Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Argentina Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Argentina Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
    • MEA
      • MEA Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
        • Adenovirus
        • Retrovirus
        • Adeno-Associated Virus (AAV)
        • Lentivirus
        • Plasmids
        • Others
      • MEA Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
        • Upstream Manufacturing
          • Vector Amplification & Expansion
          • Vector Recovery/Harvesting
        • Downstream Manufacturing
          • Purification
          • Fill Finish
      • MEA Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
        • Antisense & RNAi Therapy
        • Gene Therapy
        • Cell Therapy
        • Vaccinology
        • Research Applications
      • MEA Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
        • Pharmaceutical and Biopharmaceutical Companies
        • Research Institutes
      • MEA Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
        • Cancer
        • Genetic Disorders
        • Infectious Diseases
        • Others
      • South Africa
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • South Africa Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Saudi Arabia
        • Saudi Arabia Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • South Africa Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • South Africa Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • UAE
        • UAE Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • UAE Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • UAE Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • UAE Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • UAE Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others
      • Kuwait
        • Kuwait Viral Vectors And Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2018 - 2030)
          • Adenovirus
          • Retrovirus
          • Adeno-Associated Virus (AAV)
          • Lentivirus
          • Plasmids
          • Others
        • Kuwait Viral Vectors And Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
          • Upstream Manufacturing
            • Vector Amplification & Expansion
            • Vector Recovery/Harvesting
          • Downstream Manufacturing
            • Purification
            • Fill Finish
        • Kuwait Viral Vectors And Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)
          • Antisense & RNAi Therapy
          • Gene Therapy
          • Cell Therapy
          • Vaccinology
          • Research Applications
        • Kuwait Viral Vectors And Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)
          • Pharmaceutical and Biopharmaceutical Companies
          • Research Institutes
        • Kuwait Viral Vectors And Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)
          • Cancer
          • Genetic Disorders
          • Infectious Diseases
          • Others

Viral Vectors And Plasmid DNA Manufacturing Market Dynamics

Driver: Robust Pipeline for Gene Therapies and Viral Vector Vaccines

Researchers are working to develop gene-based therapies for treating a wide range of diseases. Although the number of patients receiving gene therapies is less, the future of gene therapy holds great promise as it is expected to revolutionize the treatment regime by targeting the genes responsible for disease pathogenesis. Many universities and institutes have a broad portfolio of gene therapy products in the pipeline. This is expected to boost the gene therapy market growth. For example, the University of Massachusetts Medical School and the University of Utah are conducting some clinical trials aimed at developing and introducing new gene therapies.

Driver: Technological Advancements in Manufacturing Vectors

Over the past few years, the number of vectors manufactured has been suitable only for phase I/II clinical trials. Currently, gene therapy vector manufacturing methods are not suitable for large-scale production. This is one of the major issues faced by market players. Successful clinical trials pertaining to gene therapy-based treatments for common indications, such as Parkinson’s disease, rheumatoid arthritis, and Alzheimer’s disease, have facilitated the large-scale production of gene therapy vectors. This has led to a high demand for new technologies to support large-scale vector production. For example, CEVEC develops solutions to address the aforementioned challenges by developing cell lines that can be grown in suspension in bioreactors of larger working volumes. The company introduced a novel helper-virus-free stable production system for scalable manufacturing of AAV vectors to meet the growing demand for vectors by gene therapy companies.

Restraint: Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy and Viral Vectors

As gene therapy involves modifications or alterations in the set of genes, it has raised several ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic ailment. However, it is anticipated to affect the fetus development significantly. Furthermore, the development and production of gene therapy products involve collaborative efforts from key participants, such as government bodies and companies. Regulatory agencies, such as the FDA, have established several guidance documents demonstrating preclinical & clinical activities as a key to the regulation and review of gene therapy products. However, these guidelines by regulatory bodies of various countries are not uniform. Guidance from the CDC and the National Institutes of Health (NIH) is not well-defined.

What Does This Report Include?

This section will provide insights into the contents included in this viral vectors and plasmid DNA manufacturing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Viral vectors and plasmid DNA manufacturing market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Viral vectors and plasmid DNA manufacturing market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Research Methodology

Grand View Research employs a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:

Preliminary data mining

Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.

Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.

Statistical model

Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.

Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:

    • Market drivers and restraints, along with their current and expected impact
    • Raw material scenario and supply v/s price trends
    • Regulatory scenario and expected developments
    • Current capacity and expected capacity additions up to 2030

We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.

Primary validation

This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts, and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation but also provide critical insights into the market, current business scenario, and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:

    • Market-leading companies
    • Raw material suppliers
    • Product distributors
    • Buyers

The key objectives of primary research are as follows:

    • To validate our data in terms of accuracy and acceptability
    • To gain an insight in to the current market and future expectations

Data Collection Matrix

Perspective

Primary research

Secondary research

Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data

Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Industry Analysis Matrix

Qualitative analysis

Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

 

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
Jump to content
pdf icn

GET A FREE SAMPLE

arrow icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

Or view our licence options:

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.